{"content":"<li class=\"n-box-item date-title\" data-end=\"1576817999\" data-start=\"1576731600\" data-txt=\"Monday, December 23, 2019\">Thursday, December 19, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3527652\" data-ts=\"1576813812\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MITK\" target=\"_blank\">MITK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527652-mitek-up-5-on-share-repurchase-announcement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mitek up 5% on share repurchase announcement</a></h4><ul> <li>Mitek (NASDAQ:<a href='https://seekingalpha.com/symbol/MITK' title='Mitek Systems, Inc.'>MITK</a>) <font color=\"green\">up 5.3%</font> as board authorized to repurchase up to $10M of its outstanding common stock.</li>   <li>The share repurchase program is effective immediately and will expire December 16, 2020.</li><li>MITK  <font color=\"green\">+5.3%</font> after hours to  $7.65</li><li>Source: <a href=\"https://seekingalpha.com/pr/17734069-mitek-announces-10-million-share-repurchase-program\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3527652\" data-linked=\"Mitek up 5% on share repurchase announcement\" data-tweet=\"$MITK - Mitek up 5% on share repurchase announcement https://seekingalpha.com/news/3527652-mitek-up-5-on-share-repurchase-announcement?source=tweet\" data-url=\"https://seekingalpha.com/news/3527652-mitek-up-5-on-share-repurchase-announcement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527644\" data-ts=\"1576813210\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UDR\" target=\"_blank\">UDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527644-udr-weighing-potential-deal-mack-cali-realty-reuters\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UDR weighing potential deal with Mack-Cali Realty - Reuters</a></h4><ul><li>UDR Inc. (NYSE:<a href='https://seekingalpha.com/symbol/UDR' title='UDR, Inc.'>UDR</a>) <font color=\"green\">+2.6%</font> and Mack-Cali Realty (NYSE:<a href='https://seekingalpha.com/symbol/CLI' title='Mack-Cali Realty Corporation'>CLI</a>) <font color=\"green\">+3.8%</font> after-hours following a Reuters report that the two property firms are <a href=\"https://www.reuters.com/article/us-mack-cali-rlty-m-a-udr-exclusive/exclusive-property-firm-udr-explores-deal-with-mack-cali-realty-sources-idUSKBN1YN2TR\" target=\"_blank\">exploring a potential combination</a>.</li><li>UDR is said to be in talks about partnering on its bid for CLI with  investment firm Rizk Ventures CEO Thomas Rizk, who was CEO of  Mack-Cali during 1997-99 and previously led Cali Realty, whose  merger with Mack Company created Mack-Cali in 1997.</li><li>UDR is interested in CLI's residential properties while Rizk covets some of the company's commercial office space, according to the report.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527644\" data-linked=\"UDR weighing potential deal with Mack-Cali Realty - Reuters\" data-tweet=\"$UDR $CLI - UDR weighing potential deal with Mack-Cali Realty - Reuters https://seekingalpha.com/news/3527644-udr-weighing-potential-deal-mack-cali-realty-reuters?source=tweet\" data-url=\"https://seekingalpha.com/news/3527644-udr-weighing-potential-deal-mack-cali-realty-reuters\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527620\" data-ts=\"1576811757\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABEO\" target=\"_blank\">ABEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527620-abeona-readies-equity-offering-shares-down-27-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abeona readies equity offering; shares down 27% after hours</a></h4><ul><li>Abeona Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ABEO' title='Abeona Therapeutics Inc.'>ABEO</a>) slumps <font color=\"red\">27%</font> after hours in reaction to its planned <a href=\"https://seekingalpha.com/pr/17734051-abeona-therapeutics-announces-public-offering-of-common-stock-and-pre-funded-warrants\" target=\"_blank\">public offering</a> of common stock and pre-funded warrants. Prices, volumes and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527620\" data-linked=\"Abeona readies equity offering; shares down 27% after hours\" data-tweet=\"$ABEO - Abeona readies equity offering; shares down 27% after hours https://seekingalpha.com/news/3527620-abeona-readies-equity-offering-shares-down-27-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3527620-abeona-readies-equity-offering-shares-down-27-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527619\" data-ts=\"1576811584\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBAY\" target=\"_blank\">CBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527619-cymabay-to-cut-60-of-workforce-shares-down-8-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CymaBay to cut 60% of workforce; shares down 8% after hours</a></h4><ul><li>Aimed at cutting operating expenses, CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics, Inc.'>CBAY</a>) will <a href=\"https://www.sec.gov/ix?doc=/Archives/edgar/data/1042074/000119312519319305/d794520d8k.htm\" target=\"_blank\">terminate 60% of its employees</a>, along with other measures, as it explores strategic alternatives. The majority of the layoffs will happen this month. The company will record a charge of $3-4M, mostly this quarter, for severance payments and other costs.</li><li>It has also finalized its decision to stop clinical trials evaluating seladelpar for primary biliary cholangitis.</li><li>Shares down <font color=\"red\">8%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527619\" data-linked=\"CymaBay to cut 60% of workforce; shares down 8% after hours\" data-tweet=\"$CBAY - CymaBay to cut 60% of workforce; shares down 8% after hours https://seekingalpha.com/news/3527619-cymabay-to-cut-60-of-workforce-shares-down-8-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3527619-cymabay-to-cut-60-of-workforce-shares-down-8-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527614\" data-ts=\"1576795460\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527614-camp-knx-uctt-and-air-among-notable-after-hours-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CAMP, KNX, UCTT and AIR among notable after hours movers</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SCHL' title='Scholastic Corporation'>SCHL</a> <font color=\"green\">+10%</font>. <a href='https://seekingalpha.com/symbol/AIR' title='AAR Corp.'>AIR</a> <font color=\"green\">+7.1%</font>. <a href='https://seekingalpha.com/symbol/UCTT' title='Ultra Clean Holdings, Inc.'>UCTT</a> <font color=\"green\">+2.9%</font>. <a href='https://seekingalpha.com/symbol/VRTV' title='Veritiv Corporation'>VRTV</a> <font color=\"green\">+2.7%</font>. <a href='https://seekingalpha.com/symbol/HCAT' title='Health Catalyst, Inc.'>HCAT</a> <font color=\"green\">+2.2%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CAMP' title='CalAmp Corp.'>CAMP</a> <font color=\"red\">-11%</font>. <a href='https://seekingalpha.com/symbol/SIGA' title='SIGA Technologies, Inc.'>SIGA</a> <font color=\"red\">-4.6%</font>. <a href='https://seekingalpha.com/symbol/BRY' title='Berry Petroleum Corporation'>BRY</a> <font color=\"red\">-2.9%</font>. <a href='https://seekingalpha.com/symbol/KNX' title='Knight-Swift Transportation Holdings Inc.'>KNX</a> <font color=\"red\">-2.7%</font>. <a href='https://seekingalpha.com/symbol/EVC' title='Entravision Communications Corporation'>EVC</a> <font color=\"red\">-2.6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527614\" data-linked=\"CAMP, KNX, UCTT and AIR among notable after hours movers\" data-tweet=\"$SCHL $AIR $UCTT - CAMP, KNX, UCTT and AIR among notable after hours movers https://seekingalpha.com/news/3527614-camp-knx-uctt-and-air-among-notable-after-hours-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527614-camp-knx-uctt-and-air-among-notable-after-hours-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527598\" data-ts=\"1576792213\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KNX\" target=\"_blank\">KNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527598-knight-swiftminus-3_6-after-q4-guidance-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Knight-Swift -3.6% after Q4 guidance cut</a></h4><ul><li>Knight-Swift Transportation (NYSE:<a href='https://seekingalpha.com/symbol/KNX' title='Knight-Swift Transportation Holdings Inc.'>KNX</a>)<font color=\"red\"> slips 3.6%</font> in after-hours trading after<a href=\"https://seekingalpha.com/pr/17733825-knight-swift-transportation-holdings-inc-announces-updated-fourth-quarter-earnings-guidance\" target=\"_blank\"> cutting Q4 guidance</a> due to an oversupply of truckload capacity in its industry.</li><li>Now sees Q4 adjusted EPS of 55 cents-52 cents compared with its previous guidance of 62 cents to 65 cents; consensus estimate is 62 cents.</li><li>The company expects to revise its Q1 2020 guidance and provide Q2 guidance with its Q4 earnings release in January.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527598\" data-linked=\"Knight-Swift -3.6% after Q4 guidance cut\" data-tweet=\"$KNX - Knight-Swift -3.6% after Q4 guidance cut https://seekingalpha.com/news/3527598-knight-swiftminus-3_6-after-q4-guidance-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3527598-knight-swiftminus-3_6-after-q4-guidance-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527580\" data-ts=\"1576791135\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAMP\" target=\"_blank\">CAMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527580-calamp-drops-13-after-q3-non-gaap-eps-matches\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CalAmp drops 13% after Q3 non-GAAP EPS matches</a></h4><ul><li>CalAmp (NASDAQ:<a href='https://seekingalpha.com/symbol/CAMP' title='CalAmp Corp.'>CAMP</a>)<font color=\"red\"> sinks 13%</font> in after-hours trading after fiscal <a href=\"https://seekingalpha.com/pr/17733848-calamp-reports-fiscal-2020-third-quarter-financial-results\" target=\"_blank\">Q3 non-GAAP EPS</a> of 15 cents matches the consensus estimate and adjusted EBITDA margin narrows to 11% from 13% a year ago.</li><li>Non-GAAP EPS compares with 25 cents in the year-ago quarter.</li><li>Revenue for the quarter ended Nov. 30, 2019 of $96.6M beats the average analyst estimate of $95.1M and rose 9% Y/Y and 4% Q/Q.</li><li>Q3 software and subscriptions service revenue of $33.4M increased 68% Y/Y.</li><li>Q3 telematics systems revenue of $63.2M fell from $68.6M a year ago.</li><li>Gross margin of 38% reflects the impact of unfavorable product mix coupled with incremental charges for excess and obsolete inventory and manufacturing variances related to the closure of the U.S. manufacturing facility</li><li><a href=\"https://investor.calamp.com/home/default.aspx\" target=\"_blank\">Conference call</a> at 4:30 PM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3527546-calamp-eps-in-line-beats-on-revenue\" target=\"_blank\">CalAmp EPS in-line, beats on revenue</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3527580\" data-linked=\"CalAmp drops 13% after Q3 non-GAAP EPS matches\" data-tweet=\"$CAMP - CalAmp drops 13% after Q3 non-GAAP EPS matches https://seekingalpha.com/news/3527580-calamp-drops-13-after-q3-non-gaap-eps-matches?source=tweet\" data-url=\"https://seekingalpha.com/news/3527580-calamp-drops-13-after-q3-non-gaap-eps-matches\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527569\" data-ts=\"1576790688\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527569-biogen-to-buy-back-5b-of-stock\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biogen to buy back $5B more of stock</a></h4><ul><li>The board of Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) has <a href=\"https://www.sec.gov/ix?doc=/Archives/edgar/data/875045/000119312519319126/d853220d8k.htm\" target=\"_blank\">authorized </a>the repurchase of up to an additional $5B of its outstanding common stock. All reacquired shares will be retired.</li><li>The share buy back program authorized in March is still in effect.</li><li>Shares up <font color=\"green\">1%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527569\" data-linked=\"Biogen to buy back $5B more of stock\" data-tweet=\"$BIIB - Biogen to buy back $5B more of stock https://seekingalpha.com/news/3527569-biogen-to-buy-back-5b-of-stock?source=tweet\" data-url=\"https://seekingalpha.com/news/3527569-biogen-to-buy-back-5b-of-stock\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527566\" data-ts=\"1576790625\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527566-nike-falls-back-from-all-time-high\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nike falls back from all-time high</a></h4><ul>  <li>Nike (NYSE:<a href='https://seekingalpha.com/symbol/NKE' title='NIKE, Inc.'>NKE</a>) slips after <a href=\"https://seekingalpha.com/pr/17733876-nike-inc-reports-fiscal-2020-second-quarter-results\" target=\"_blank\">FQ2</a> EPS arrives in ahead of even the highest estimate turned in by analysts, but the tiniest of margin misses disrupted the earnings party for the Swoosh.</li>  <li>The company reports North America revenue rose 5.0% to $3.98B and EMEA revenue was up 10.0% to $2.54B. Greater China revenue soared 20% to $1.85B during the quarter.</li>  <li>Footwear sales rose 12% and apparel sales were up 10%.</li>   <li>Gross margin came in slightly behind expectations at 44.0% of sales vs. 44.1% consensus and 43.8% a year ago. Higher average selling prices and margin expansion in Nike Direct and Converse partially offset impacts from higher product costs, primarily due to incremental tariffs in North America.</li><li>SG&amp;A expenses rose 6% during the quarter to $3.3B.</li>  <li>\"As we deliver a relentless flow of innovation and scale Nike's digital advantage, we are positioned for even greater competitive separation and long-term shareholder value creation.\" notes CFO Andy Campion on the path ahead.</li>   <li>Shares of Nike are <font color=\"red\">down 2.31%</font> in AH trading to $98.76. An all-time high on Nike of $101.15 was printed earlier today.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3527554-nike-eps-beats-0_12-beats-on-revenue\" target=\"_blank\">Nike EPS beats by $0.12, beats on revenue</a> (Dec. 19)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3527566\" data-linked=\"Nike falls back from all-time high\" data-tweet=\"$NKE - Nike falls back from all-time high https://seekingalpha.com/news/3527566-nike-falls-back-from-all-time-high?source=tweet\" data-url=\"https://seekingalpha.com/news/3527566-nike-falls-back-from-all-time-high\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527548\" data-ts=\"1576789749\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KNX\" target=\"_blank\">KNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527548-knight-swift-lowers-profit-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Knight-Swift lowers profit guidance</a></h4><ul> <li>Knight-Swift Transportation (NYSE:<a href='https://seekingalpha.com/symbol/KNX' title='Knight-Swift Transportation Holdings Inc.'>KNX</a>) says it expects Q4 EPS of $0.50 to $0.52 vs. $0.62 to $0.65 prior range and $0.62 consensus.</li><li>The company says the industry continues to be oversupplied with truckload capacity, which led to more muted seasonal improvement in the freight market in Q3-Q4. The development led to fewer than expected seasonal high-yield freight opportunities and rate increases were less than anticipated.</li><li>Shares of KNX are <font color=\"red\">down 4.40%</font> AH.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17733825-knight-swift-transportation-holdings-inc-announces-updated-fourth-quarter-earnings-guidance\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3527548\" data-linked=\"Knight-Swift lowers profit guidance\" data-tweet=\"$KNX - Knight-Swift lowers profit guidance https://seekingalpha.com/news/3527548-knight-swift-lowers-profit-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3527548-knight-swift-lowers-profit-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527543\" data-ts=\"1576789435\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIR\" target=\"_blank\">AIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527543-aar-eps-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AAR EPS beats by $0.04, beats on revenue</a></h4><ul><li>AAR (NYSE:<a href='https://seekingalpha.com/symbol/AIR' title='AAR Corp.'>AIR</a>): Q2 Non-GAAP EPS of $0.64 <font color=\"green\">beats by $0.04</font>; GAAP EPS of $0.57 <font color=\"red\">misses by $0.02</font>.</li><li>Revenue of $560.9M (+13.7% Y/Y) <font color=\"green\">beats by $34.74M</font>.</li><li>Shares <font color=\"green\">+2.17%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17733815-aar-reports-second-quarter-fiscal-year-2020-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3527543\" data-linked=\"AAR EPS beats by $0.04, beats on revenue\" data-tweet=\"$AIR - AAR EPS beats by $0.04, beats on revenue https://seekingalpha.com/news/3527543-aar-eps-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3527543-aar-eps-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527542\" data-ts=\"1576789390\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCHL\" target=\"_blank\">SCHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527542-scholastic-eps-beats-0_25-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scholastic EPS beats by $0.25, beats on revenue</a></h4><ul><li>Scholastic (NASDAQ:<a href='https://seekingalpha.com/symbol/SCHL' title='Scholastic Corporation'>SCHL</a>): Q2 Non-GAAP EPS of $2.06; GAAP EPS of $2.02 <font color=\"green\">beats by $0.25</font>.</li><li>Revenue of $597.2M (-1.2% Y/Y) <font color=\"green\">beats by $6.2M</font>.</li><li>Shares <font color=\"green\">+11.15%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17733810-scholastic-reports-fiscal-2020-second-quarter-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3527542\" data-linked=\"Scholastic EPS beats by $0.25, beats on revenue\" data-tweet=\"$SCHL - Scholastic EPS beats by $0.25, beats on revenue https://seekingalpha.com/news/3527542-scholastic-eps-beats-0_25-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3527542-scholastic-eps-beats-0_25-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527538\" data-ts=\"1576788348\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNPR\" target=\"_blank\">MNPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527538-monopar-up-big-in-u-s-debut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Monopar up big in U.S. debut</a></h4><ul><li>Monopar Therapeutics (<a href='https://seekingalpha.com/symbol/MNPR' title='Monopar Therapeutics'>MNPR</a> <font color=\"red\">N/A</font>) has faced two volatility halts in its first day of trading. Shares are currently exchanging hands at $26.46, up <font color=\"green\">231%</font> from its $8 IPO price.</li><li><a href=\"https://seekingalpha.com/news/3492410-monopar-therapeutics-on-deck-for-ipo\" target=\"_blank\">Lead candidate</a> is Fast Track-tagged Validive (clonidine mucobuccal tablet) for the treatment of oral mucositis in oropharyngeal cancer patients undergoing chemo.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527538\" data-linked=\"Monopar up big in U.S. debut\" data-tweet=\"$MNPR - Monopar up big in U.S. debut https://seekingalpha.com/news/3527538-monopar-up-big-in-u-s-debut?source=tweet\" data-url=\"https://seekingalpha.com/news/3527538-monopar-up-big-in-u-s-debut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527530\" data-ts=\"1576785907\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527530-telaria-and-greensky-among-tech-gainers-gse-systems-and-dpw-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Telaria and GreenSky among Tech gainers; GSE Systems and DPW among losers</a></h4><ul><li><b>Gainers: </b>Telaria (NYSE:<a href='https://seekingalpha.com/symbol/TLRA' title='Telaria, Inc.'>TLRA</a>) <font color=\"green\">+12%</font>. GreenSky (NASDAQ:<a href='https://seekingalpha.com/symbol/GSKY' title='GreenSky, Inc.'>GSKY</a>) <font color=\"green\">+10%</font>. GSE Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/GVP' title='GSE Systems, Inc.'>GVP</a>) <font color=\"green\">+10%</font>. DPW Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a>) <font color=\"green\">+8%</font>. Intelsat (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat S.A.'>I</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>Xperi (NASDAQ:<a href='https://seekingalpha.com/symbol/XPER' title='Xperi Corporation'>XPER</a>) <font color=\"red\">-11%</font>. Super League Gaming (NASDAQ:<a href='https://seekingalpha.com/symbol/SLGG' title='Super League Gaming, Inc.'>SLGG</a>) <font color=\"red\">-11%</font>. YayYo (NASDAQ:<a href='https://seekingalpha.com/symbol/YAYO' title='YayYo, Inc.'>YAYO</a>) <font color=\"red\">-10%</font>. Creative Realities (NASDAQ:<a href='https://seekingalpha.com/symbol/CREX' title='Creative Realities, Inc.'>CREX</a>) <font color=\"red\">-10%</font>. Aurora Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/JG' title='Aurora Mobile Limited'>JG</a>) <font color=\"red\">-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527530\" data-linked=\"Telaria and GreenSky among Tech gainers; GSE Systems and DPW among losers\" data-tweet=\"$TLRA $GSKY $GVP - Telaria and GreenSky among Tech gainers; GSE Systems and DPW among losers https://seekingalpha.com/news/3527530-telaria-and-greensky-among-tech-gainers-gse-systems-and-dpw-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527530-telaria-and-greensky-among-tech-gainers-gse-systems-and-dpw-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527522\" data-ts=\"1576783519\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LYV\" target=\"_blank\">LYV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527522-live-nation-jumps-on-report-of-doj-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Live Nation jumps on report of DOJ deal</a></h4><ul> <li>Live Nation Entertainment (<a href='https://seekingalpha.com/symbol/LYV' title='Live Nation Entertainment, Inc.'>LYV</a> <font color='green'>+10.1%</font>) rallies after the company is said to have <a href=\"https://www.cnbc.com/2019/12/19/live-nation-justice-department-to-announce-a-settlement-over-ticketing-practices-a-source-says.html\" target=\"_blank\">settled</a> with the DOJ and avoided a lawsuit over ticketing practices.</li> <li>CNBC reports Live Nation will pay DOJ attorney fees in the low \"millions\" of dollars range as part of the deal.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3527522\" data-linked=\"Live Nation jumps on report of DOJ deal\" data-tweet=\"$LYV - Live Nation jumps on report of DOJ deal https://seekingalpha.com/news/3527522-live-nation-jumps-on-report-of-doj-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3527522-live-nation-jumps-on-report-of-doj-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527521\" data-ts=\"1576783228\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527521-chicken-peers-follow-sanderson-farms-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chicken peers follow Sanderson Farms higher</a></h4><ul> <li>Tyson Foods (<a href='https://seekingalpha.com/symbol/TSN' title='Tyson Foods, Inc.'>TSN</a> <font color='green'>+1.3%</font>) and Pilgrim's Pride (<a href='https://seekingalpha.com/symbol/PPC' title='Pilgrim&#39;s Pride Corporation'>PPC</a> <font color='green'>+3.5%</font>) trade higher after a positive assessment from Sanderson Farms on chicken prices.</li> <li>\"The protein deficit caused by African swine fever in China and other countries, recently well-publicized chicken sandwich features at quick serve restaurants, and expected higher retail pork and beef prices should all support stronger poultry markets as we move into 2020,\" noted Sanderson Farms CEO Joel Sanderson.</li><li>The chicken sandwich race at fast-food restaurants is expected to be just as strong in 2020.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3527384-sanderson-farmsplus-3-on-improved-pricing-outlook\" target=\"_blank\">Sanderson Farms +3% on improved pricing outlook</a> (Dec. 19)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527521\" data-linked=\"Chicken peers follow Sanderson Farms higher\" data-tweet=\"$TSN $PPC - Chicken peers follow Sanderson Farms higher https://seekingalpha.com/news/3527521-chicken-peers-follow-sanderson-farms-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3527521-chicken-peers-follow-sanderson-farms-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527518\" data-ts=\"1576782166\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527518-seadrill-and-china-natural-resources-among-energy-materials-gainers-mcdermott-and-centrus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seadrill and China Natural Resources among Energy/Materials gainers; McDermott and Centrus Energy among losers</a></h4><ul><li><b>Gainers: </b>Seadrill (NYSE:<a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited'>SDRL</a>) <font color=\"green\">+15%</font>. China Natural Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/CHNR' title='China Natural Resources, Inc.'>CHNR</a>) <font color=\"green\">+14%</font>. Contango Oil &amp; Gas (NYSEMKT:<a href='https://seekingalpha.com/symbol/MCF' title='Contango Oil & Gas Company'>MCF</a>) <font color=\"green\">+10%</font>. Noble Corporation (NYSE:<a href='https://seekingalpha.com/symbol/NE' title='Noble Corporation plc'>NE</a>) <font color=\"green\">+9%</font>. HighPoint Resources (NYSE:<a href='https://seekingalpha.com/symbol/HPR' title='HighPoint Resources Corporation'>HPR</a>) <font color=\"green\">+9%</font>.</li><li><b>Losers: </b>McDermott (NYSE:<a href='https://seekingalpha.com/symbol/MDR' title='McDermott International, Inc.'>MDR</a>) <font color=\"red\">-10%</font>. Centrus Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/LEU' title='Centrus Energy Corp.'>LEU</a>) <font color=\"red\">-7%</font>. FTS International (NYSE:<a href='https://seekingalpha.com/symbol/FTSI' title='FTS International, Inc.'>FTSI</a>) <font color=\"red\">-5%</font>. Chaparral Energy (NYSE:<a href='https://seekingalpha.com/symbol/CHAP' title='Chaparral Energy, Inc.'>CHAP</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527518\" data-linked=\"Seadrill and China Natural Resources among Energy/Materials gainers; McDermott and Centrus Energy among losers\" data-tweet=\"$SDRL $CHNR $MCF - Seadrill and China Natural Resources among Energy/Materials gainers; McDermott and Centrus Energy among losers https://seekingalpha.com/news/3527518-seadrill-and-china-natural-resources-among-energy-materials-gainers-mcdermott-and-centrus?source=tweet\" data-url=\"https://seekingalpha.com/news/3527518-seadrill-and-china-natural-resources-among-energy-materials-gainers-mcdermott-and-centrus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527512\" data-ts=\"1576780212\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MED\" target=\"_blank\">MED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527512-medifast-up-8-on-rumored-go-private-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medifast up 8% on rumored go-private bid</a></h4><ul><li>Medifast (<a href='https://seekingalpha.com/symbol/MED' title='Medifast, Inc.'>MED</a> <font color=\"green\">+7.6%</font>) is up, albeit on below-average volume, in apparent response to a report that shareholder Engaged Capital, owner of 9.99% stake, is mulling a bid to take the company private.</li><li><strong>Update</strong>: Bloomberg <a href=\"https://www.bloomberg.com/news/articles/2019-12-19/engaged-capital-is-said-to-consider-bid-for-medifast?srnd=premium\" target=\"_blank\">reports </a>that, according to informed sources, Engaged is considering a bid. It currently owns ~15% of the weight-loss meal provider.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527512\" data-linked=\"Medifast up 8% on rumored go-private bid\" data-tweet=\"$MED - Medifast up 8% on rumored go-private bid https://seekingalpha.com/news/3527512-medifast-up-8-on-rumored-go-private-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3527512-medifast-up-8-on-rumored-go-private-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527506\" data-ts=\"1576778650\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527506-southwest-georgia-financial-and-msb-financial-financial-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Southwest Georgia Financial and MSB Financial as Financial gainers</a></h4><ul><li><b>Gainers: </b>Southwest Georgia Financial (NYSEMKT:<a href='https://seekingalpha.com/symbol/SGB' title='Southwest Georgia Financial Corporation'>SGB</a>) <font color=\"green\">+48%</font>. MSB Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/MSBF' title='MSB Financial Corp.'>MSBF</a>) <font color=\"green\">+17%</font>.</li><li><b>Losers: </b>Green Dot (NYSE:<a href='https://seekingalpha.com/symbol/GDOT' title='Green Dot Corporation'>GDOT</a>) <font color=\"red\">-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527506\" data-linked=\"Southwest Georgia Financial and MSB Financial as Financial gainers\" data-tweet=\"$SGB $MSBF $GDOT - Southwest Georgia Financial and MSB Financial as Financial gainers https://seekingalpha.com/news/3527506-southwest-georgia-financial-and-msb-financial-financial-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527506-southwest-georgia-financial-and-msb-financial-financial-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527505\" data-ts=\"1576778634\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NMMCF\" target=\"_blank\">NMMCF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527505-nmc-health-takes-exception-to-misleading-muddy-waters-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NMC Health takes exception to &quot;misleading&quot; Muddy Waters report</a></h4><ul><li>In a <a href=\"https://cf-cdn.nmc.ae/Uploads/InvestorRelations/nmc-health-plc-response-to-recent-report-19-dec-2019-adb66d0b-4047-4d4d-94f2-fb9a84d2d301.pdf\" target=\"_blank\">statement</a>, NMC Health (<a href='https://seekingalpha.com/symbol/NMMCF' title='NMC Health Plc'>OTC:NMMCF</a>) regards the recent <a href=\"https://seekingalpha.com/news/3526811-nmc-health-down-39-on-bearish-muddy-waters-report\" target=\"_blank\">bearish report</a> from Muddy Waters as \"false and misleading\" citing its track record of \"significant, open and increasingly detailed disclosures\" to the market.</li><li>The company then defends each point in MW's short thesis.</li><li>The stock is down <font color=\"red\">13%</font>, albeit on turnover of only 6,500 shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527505\" data-linked=\"NMC Health takes exception to &quot;misleading&quot; Muddy Waters report\" data-tweet=\"$NMMCF $NMHLY - NMC Health takes exception to &quot;misleading&quot; Muddy Waters report https://seekingalpha.com/news/3527505-nmc-health-takes-exception-to-misleading-muddy-waters-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3527505-nmc-health-takes-exception-to-misleading-muddy-waters-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527503\" data-ts=\"1576778386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527503-shiloh-industries-leads-industrial-gainers-apogee-enterprises-tops-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shiloh Industries leads industrial gainers; Apogee Enterprises tops losers</a></h4><ul><li><b>Gainers: </b>Shiloh Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/SHLO' title='Shiloh Industries, Inc.'>SHLO</a>) <font color=\"green\">+6%</font>. LSI Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/LYTS' title='LSI Industries Inc.'>LYTS</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Apogee Enterprises (NASDAQ:<a href='https://seekingalpha.com/symbol/APOG' title='Apogee Enterprises, Inc.'>APOG</a>) <font color=\"red\">-21%</font>. NF Energy Saving (NASDAQ:<a href='https://seekingalpha.com/symbol/BIMI' title='NF Energy Saving Corporation'>BIMI</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527503\" data-linked=\"Shiloh Industries leads industrial gainers; Apogee Enterprises tops losers\" data-tweet=\"$SHLO $LYTS $APOG - Shiloh Industries leads industrial gainers; Apogee Enterprises tops losers https://seekingalpha.com/news/3527503-shiloh-industries-leads-industrial-gainers-apogee-enterprises-tops-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527503-shiloh-industries-leads-industrial-gainers-apogee-enterprises-tops-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527499\" data-ts=\"1576777417\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527499-rad-ino-mdr-and-asna-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RAD, INO, MDR and ASNA among midday movers</a></h4><ul><li><strong>Gainers:</strong> Southwest Georgia Financial (NYSEMKT:<a href='https://seekingalpha.com/symbol/SGB' title='Southwest Georgia Financial Corporation'>SGB</a>) <font color=\"green\">+48%</font>.</li><li>Rite Aid (NYSE:<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>) <font color=\"green\">+41%</font>.</li><li>Paratek Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a>) <font color=\"green\">+38%</font>.</li><li>Catalyst Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a>) <font color=\"green\">+37%</font>.</li><li>Selecta Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SELB' title='Selecta Biosciences, Inc.'>SELB</a>) <font color=\"green\">+37%</font>.</li><li>ENDRA Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NDRA' title='ENDRA Life Sciences Inc.'>NDRA</a>) <font color=\"green\">+33%</font>.</li><li>PLx Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/PLXP' title='PLx Pharma Inc.'>PLXP</a>) <font color=\"green\">+31%</font>.</li><li>Inovio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a>) <font color=\"green\">+27%</font>.</li><li>PhaseBio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PHAS' title='PhaseBio Pharmaceuticals, Inc.'>PHAS</a>) <font color=\"green\">+23%</font>.</li><li>Stereotaxis (NYSEMKT:<a href='https://seekingalpha.com/symbol/STXS' title='Stereotaxis, Inc.'>STXS</a>) <font color=\"green\">+22%</font>.</li><li><strong>Losers: </strong>Apogee Enterprises (NASDAQ:<a href='https://seekingalpha.com/symbol/APOG' title='Apogee Enterprises, Inc.'>APOG</a>) <font color=\"red\">-21%</font>.</li><li>Minerva Neurosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NERV' title='Minerva Neurosciences, Inc.'>NERV</a>) <font color=\"red\">-19%</font>.</li><li>Venus Concept (NASDAQ:<a href='https://seekingalpha.com/symbol/VERO' title='Venus Concept Inc.'>VERO</a>) <font color=\"red\">-17%</font>.</li><li>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a>) <font color=\"red\">-15%</font>.</li><li>Reed's (NASDAQ:<a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a>) <font color=\"red\">-14%</font>.</li><li>Ascena Retail (NASDAQ:<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group, Inc.'>ASNA</a>) <font color=\"red\">-14%</font>.</li><li>Green Dot (NYSE:<a href='https://seekingalpha.com/symbol/GDOT' title='Green Dot Corporation'>GDOT</a>) <font color=\"red\">-13%</font>.</li><li>McDermott International (NYSE:<a href='https://seekingalpha.com/symbol/MDR' title='McDermott International, Inc.'>MDR</a>) <font color=\"red\">-12%</font>.</li><li>Super League Gaming (NASDAQ:<a href='https://seekingalpha.com/symbol/SLGG' title='Super League Gaming, Inc.'>SLGG</a>) <font color=\"red\">-12%</font>.</li><li>Herman Miller (NASDAQ:<a href='https://seekingalpha.com/symbol/MLHR' title='Herman Miller, Inc.'>MLHR</a>) <font color=\"red\">-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527499\" data-linked=\"RAD, INO, MDR and ASNA among midday movers\" data-tweet=\"$SGB $RAD $PRTK - RAD, INO, MDR and ASNA among midday movers https://seekingalpha.com/news/3527499-rad-ino-mdr-and-asna-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527499-rad-ino-mdr-and-asna-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527498\" data-ts=\"1576776380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WMGI\" target=\"_blank\">WMGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527498-wright-medical-up-2-on-reports-of-smith-nephew-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wright Medical up 2% on reports of Smith &amp; Nephew bid</a></h4><ul><li>Wright Medical Group N.V. (<a href='https://seekingalpha.com/symbol/WMGI' title='Wright Medical Group N.V.'>WMGI</a> <font color=\"green\">+1.6%</font>) perks up on over 40% higher volume in apparent response to reports that Smith &amp; Nephew (<a href='https://seekingalpha.com/symbol/SNN' title='Smith & Nephew plc'>SNN</a> <font color=\"red\">-0.6%</font>) may try to top Stryker's (<a href='https://seekingalpha.com/symbol/SYK' title='Stryker Corporation'>SYK</a> <font color=\"green\">+0.1%</font>) <a href=\"https://seekingalpha.com/news/3513487-stryker-takes-out-wright-medical-for-4b\" target=\"_blank\">$4B bid</a> announced last month.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527498\" data-linked=\"Wright Medical up 2% on reports of Smith &amp; Nephew bid\" data-tweet=\"$WMGI $SNN $SYK - Wright Medical up 2% on reports of Smith &amp; Nephew bid https://seekingalpha.com/news/3527498-wright-medical-up-2-on-reports-of-smith-nephew-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3527498-wright-medical-up-2-on-reports-of-smith-nephew-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527495\" data-ts=\"1576776056\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MGNX\" target=\"_blank\">MGNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527495-macrogenics-files-u-s-application-for-margetuximab-for-her2-breast-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MacroGenics files U.S. application for margetuximab for HER2+ breast cancer</a></h4><ul><li>MacroGenics (<a href='https://seekingalpha.com/symbol/MGNX' title='MacroGenics, Inc.'>MGNX</a> <font color=\"green\">+3.3%</font>) has <a href=\"https://seekingalpha.com/pr/17733522-macrogenics-announces-submission-of-margetuximab-biologics-license-application-to-u-s-fda\" target=\"_blank\">filed </a>its U.S. marketing application seeking approval of margetuximab for the treatment of metastatic HER2-positive breast cancer (combined with chemo).</li><li>Interim late-stage data presented last week in San Antonio showed that median overall survival in patients receiving the combo was only marginally better (21.6 months vs. 19.8 months) that Roche's Herceptin (trastuzumab) + chemo. The OS data are expected to mature in H2 2020.</li><li>Margetuximab is an HER2-targeting monoclonal antibody that the company is also developing for gastroesophageal cancer (in combination with a PD-1 inhibitor).</li></ul><div class=\"tiny-share-widget\" data-id=\"3527495\" data-linked=\"MacroGenics files U.S. application for margetuximab for HER2+ breast cancer\" data-tweet=\"$MGNX - MacroGenics files U.S. application for margetuximab for HER2+ breast cancer https://seekingalpha.com/news/3527495-macrogenics-files-u-s-application-for-margetuximab-for-her2-breast-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3527495-macrogenics-files-u-s-application-for-margetuximab-for-her2-breast-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527485\" data-ts=\"1576774547\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APOG\" target=\"_blank\">APOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527485-apogee-enterprises-slides-22-on-q3-results-miss-lowers-fy20-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apogee Enterprises slides 22% on Q3 results miss; lowers FY20 guidance</a></h4><ul><li>Apogee Enterprises (<a href='https://seekingalpha.com/symbol/APOG' title='Apogee Enterprises, Inc.'>APOG</a> <font color=\"red\">-22.2%</font>) reported Q3 revenue decline of 5.5% Y/Y to $337.92M, and net earnings of $15.23M (-30.4% Y/Y).</li><li>Company says Q3 results were below expectation, driven by Architectural Framing Systems, leading to reduced FY20 outlook.</li><li>Sales by segments: Architectural Framing Systems $165.62M (-9% Y/Y); Architectural Glass $89.43M (-9% Y/Y); Architectural Services $69.04M (-5% Y/Y); and Large-Scale Optical $24.4M (+4% Y/Y).</li><li>Q3 Gross margin <font color=\"red\">declined by 152 bps</font> to 22%; and operating margin <font color=\"red\">declined by 240 bps</font> to 6.4%.</li><li>Adj. EBITDA was $33.66M (-21.2% Y/Y); and margin <font color=\"red\">declined by 197 bps</font> to 9.9%.</li><li>Architectural Services backlog increased by 21% Y/Y to $607M.</li><li>Net cash provided by operating activities YTD was $53.6M, compared to $70.64M a year ago.</li><li><strong>FY20 Guidance, lowered: </strong>Revenue growth flat to 1% (prior 1% to 3%); EPS $2.15 to $2.30 (prior $3 to $3.2); tax rate of ~24.5%; and Capex of ~$55M (prior $60M to $65M).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3527330-apogee-eps-misses-0_19-misses-on-revenue\" target=\"_blank\">Apogee EPS misses by $0.19, misses on revenue</a> (Dec. 19)</li><li><a href=\"https://seekingalpha.com/article/4313330-apogee-enterprises-inc-2020-q3-results-earnings-call-presentation\" target=\"_blank\">Slides</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3527485\" data-linked=\"Apogee Enterprises slides 22% on Q3 results miss; lowers FY20 guidance\" data-tweet=\"$APOG - Apogee Enterprises slides 22% on Q3 results miss; lowers FY20 guidance https://seekingalpha.com/news/3527485-apogee-enterprises-slides-22-on-q3-results-miss-lowers-fy20-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3527485-apogee-enterprises-slides-22-on-q3-results-miss-lowers-fy20-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527472\" data-ts=\"1576771292\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DBX\" target=\"_blank\">DBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527472-dropboxplus-8-on-activist-action-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DropBox +8% on activist action talk</a></h4><ul> <li>DropBox (<a href='https://seekingalpha.com/symbol/DBX' title='Dropbox, Inc.'>DBX</a> <font color='green'>+7.5%</font>) rallies after Gordon Haskett says activist investors may take in an interest in the company in the near future.</li> <li>The firm says the high R&amp;D budget at DropBox would be a likely target of an activist looking to boost the DBX bottom line.</li> <li>DropBox trades at a four-week high off the Gordon Haskett buzz.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527472\" data-linked=\"DropBox +8% on activist action talk\" data-tweet=\"$DBX - DropBox +8% on activist action talk https://seekingalpha.com/news/3527472-dropboxplus-8-on-activist-action-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3527472-dropboxplus-8-on-activist-action-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527471\" data-ts=\"1576771280\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527471-healthcare-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers</a></h4><ul><li><b>Gainers: </b>Catalyst Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a>) <font color=\"green\">+45%</font>. ENDRA Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NDRA' title='ENDRA Life Sciences Inc.'>NDRA</a>) <font color=\"green\">+33%</font>. Selecta Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SELB' title='Selecta Biosciences, Inc.'>SELB</a>) <font color=\"green\">+32%</font>. Paratek Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a>) <font color=\"green\">+27%</font>. PLx Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/PLXP' title='PLx Pharma Inc.'>PLXP</a>) <font color=\"green\">+26%</font>.</li><li><b>Losers: </b>Venus Concept (NASDAQ:<a href='https://seekingalpha.com/symbol/VERO' title='Venus Concept Inc.'>VERO</a>) <font color=\"red\">-18%</font>. Minerva Neurosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NERV' title='Minerva Neurosciences, Inc.'>NERV</a>) <font color=\"red\">-17%</font>. Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a>) <font color=\"red\">-15%</font>. Oncolytics Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/ONCY' title='Oncolytics Biotech Inc.'>ONCY</a>) <font color=\"red\">-8%</font>. Allakos (NASDAQ:<a href='https://seekingalpha.com/symbol/ALLK' title='Allakos Inc.'>ALLK</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527471\" data-linked=\"Healthcare - Top 5 Gainers / Losers\" data-tweet=\"$CBIO $NDRA $SELB - Healthcare - Top 5 Gainers / Losers https://seekingalpha.com/news/3527471-healthcare-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527471-healthcare-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527466\" data-ts=\"1576769883\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NDRA\" target=\"_blank\">NDRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527466-endra-life-sciences-advancing-ce-mark-registration-for-taeus-flip-shares-up-30\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endra Life Sciences advancing CE Mark registration for TAEUS FLIP; shares up 30%</a></h4><ul><li>Thinly traded nano cap ENDRA Life Sciences (<a href='https://seekingalpha.com/symbol/NDRA' title='ENDRA Life Sciences Inc.'>NDRA</a> <font color=\"green\">+30%</font>) is up on an 8x surge in volume, 615K shares, in reaction to the <a href=\"https://seekingalpha.com/pr/17733048-endra-life-sciences-submits-technical-file-for-ce-mark\" target=\"_blank\">submission </a>of its technical file for CE Mark certification for its Thermo-Acoustic Enhanced Ultrasound ((<a href=\"https://endrainc.com/taeus/\" target=\"_blank\">TAEUS</a>)) FLIP device that enables more in-depth imaging similar to CT and MRI but at a much lower cost.</li><li>The company expects to receive the regulatory nod in H1 2020. It also plans to file for 510(k) clearance in the U.S. next year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527466\" data-linked=\"Endra Life Sciences advancing CE Mark registration for TAEUS FLIP; shares up 30%\" data-tweet=\"$NDRA - Endra Life Sciences advancing CE Mark registration for TAEUS FLIP; shares up 30% https://seekingalpha.com/news/3527466-endra-life-sciences-advancing-ce-mark-registration-for-taeus-flip-shares-up-30?source=tweet\" data-url=\"https://seekingalpha.com/news/3527466-endra-life-sciences-advancing-ce-mark-registration-for-taeus-flip-shares-up-30\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527463\" data-ts=\"1576769592\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527463-natural-gas-inventory-draw-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Natural gas inventory draw more than consensus</a></h4><ul><li><a href=\"http://ir.eia.gov/ngs/ngs.html\" target=\"_blank\">EIA Natural Gas Inventory:</a> <strong>-107 Bcf</strong> vs. -90 Bcf consensus, -73 Bcf last week.</li><li>Futures <font color=\"red\">-1.04%</font> to $2.260.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Trust II - ProShares Ultra Bloomberg Natural Gas'>BOIL</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares Trust II - ProShares UltraShort Bloomberg Natural Gas'>KOLD</a>, <a href='https://seekingalpha.com/symbol/UNL' title='United States 12 Month Natural Gas Fund, LP'>UNL</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527463\" data-linked=\"Natural gas inventory draw more than consensus\" data-tweet=\"$UNG $DGAZ $UGAZ - Natural gas inventory draw more than consensus https://seekingalpha.com/news/3527463-natural-gas-inventory-draw-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3527463-natural-gas-inventory-draw-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>127&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527449\" data-ts=\"1576769002\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYTR\" target=\"_blank\">CYTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527449-cytrx-up-2-on-accelerated-review-tags-for-arimoclomol\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CytRx up 2% on accelerated review tags for arimoclomol</a></h4><ul><li>Thinly traded nano cap CytRx (<a href='https://seekingalpha.com/symbol/CYTR' title='CytRx Corporation'>OTC:CYTR</a> <font color=\"green\">+1.9%</font>) perks up, albeit on turnover of only 19K shares, in response to accelerated review <a href=\"https://seekingalpha.com/pr/17733211-cytrx-corporation-highlights-significant-positive-events-from-two-licensed-drugs-arimoclomol\" target=\"_blank\">designations </a>in the U.S. for arimoclomol, out-licensed to Orphazyme A/S in 2011.</li><li>The FDA granted Breakthrough Therapy status for <a href=\"https://rarediseases.org/rare-diseases/niemann-pick-disease-type-c/\" target=\"_blank\">Niemann-Pick disease Type C</a> &#40;NPC&#41;, a rare inherited disorder characterized by the body's ability to transport lipids inside cells. Orphazyme expects to file its marketing application in H1 2020.</li><li>The agency granted Fast Track status for <a href=\"https://rarediseases.org/rare-diseases/sporadic-inclusion-body-myositis/\" target=\"_blank\">sporadic inclusion body myositis</a> (sIBM), a progressive degeneration and weakness in muscles that typically occurs in people over the age of 50.</li><li>Arimoclomol is believed to act by stimulating a cellular repair pathway via the activation of molecular chaperones (heat shock response).</li></ul><div class=\"tiny-share-widget\" data-id=\"3527449\" data-linked=\"CytRx up 2% on accelerated review tags for arimoclomol\" data-tweet=\"$CYTR - CytRx up 2% on accelerated review tags for arimoclomol https://seekingalpha.com/news/3527449-cytrx-up-2-on-accelerated-review-tags-for-arimoclomol?source=tweet\" data-url=\"https://seekingalpha.com/news/3527449-cytrx-up-2-on-accelerated-review-tags-for-arimoclomol\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527448\" data-ts=\"1576768138\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBIO\" target=\"_blank\">PBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527448-pressure-biosciences-reports-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pressure BioSciences reports Q3 results</a></h4><ul><li>Pressure BioSciences (<a href='https://seekingalpha.com/symbol/PBIO' title='Pressure BioSciences, Inc.'>OTC:PBIO</a>): Q3 GAAP EPS of -$2.20.</li><li>Revenue of $0.5M (-3.8% Y/Y)</li><li>Shares <font color=\"green\">+10%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17733342-pressure-biosciences-inc-reports-third-quarter-2019-financial-results-and-provides-business\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3527448\" data-linked=\"Pressure BioSciences reports Q3 results\" data-tweet=\"$PBIO - Pressure BioSciences reports Q3 results https://seekingalpha.com/news/3527448-pressure-biosciences-reports-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3527448-pressure-biosciences-reports-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527439\" data-ts=\"1576767037\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLUG\" target=\"_blank\">PLUG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527439-plug-power-slides-after-spruce-point-attack\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Plug Power slides after Spruce Point attack</a></h4><ul> <li>Spruce Point Capital issues a Strong Sell warning on Plug Power (<a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power Inc.'>PLUG</a> <font color='red'>-2.1%</font>).</li> <li>\"PLUG represents the worst kind of investment story: a Company that has over-promised and under-delivered for 20 years, forever failing to achieve profitability,\" says Spruce Point.</li> <li>The research firm also warns that investors don't appreciate the extent to which they have been diluted by PLUG management.</li> <li><a href=\"https://www.sprucepointcap.com/plug-power-inc/\" target=\"_blank\">Full Spruce Point Capital report on Plug Power</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527439\" data-linked=\"Plug Power slides after Spruce Point attack\" data-tweet=\"$PLUG - Plug Power slides after Spruce Point attack https://seekingalpha.com/news/3527439-plug-power-slides-after-spruce-point-attack?source=tweet\" data-url=\"https://seekingalpha.com/news/3527439-plug-power-slides-after-spruce-point-attack\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527434\" data-ts=\"1576766235\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527434-ev-dreams-tesla-over-400-bmw-over-500k\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EV dreams: Tesla over $400, BMW over 500K</a></h4><ul> <li>It looks like a good day for the electric vehicle sector.</li><li>BMW (<a href='https://seekingalpha.com/symbol/BMWYY' title='Bayerische Motoren Werke Aktiengesellschaft'>OTCPK:BMWYY</a>) crossed over the cumulative <a href=\"https://twitter.com/BMW/status/1207571350069624833\" target=\"_blank\">500K</a> unit mark for sales of the company's electrified vehicles, according to a series of late night tweets.</li> <li>While the tweet countdown is being viewed as something of a jab at Tesla's (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) Elon Musk, BMW Chairman Oliver Zipse says 500K electric vehicles sold is proof of concept on EV demand.</li> <li>BMW is probably catching Elon Musk on a good day, with shares of Tesla <font color=\"green\">up another 1.86%</font> to cross over $400 for the first time.</li><li>Elsewhere, even Nio (NYSE:<a href='https://seekingalpha.com/symbol/NIO' title='NIO Limited'>NIO</a>) is showing a little bounce today, moving <font color=\"green\">1.25% higher</font> in opening trading, while Kandi Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a>) is <font color=\"green\">up 0.88%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527434\" data-linked=\"EV dreams: Tesla over $400, BMW over 500K\" data-tweet=\"$BMWYY $TSLA $NIO - EV dreams: Tesla over $400, BMW over 500K https://seekingalpha.com/news/3527434-ev-dreams-tesla-over-400-bmw-over-500k?source=tweet\" data-url=\"https://seekingalpha.com/news/3527434-ev-dreams-tesla-over-400-bmw-over-500k\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>220&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527433\" data-ts=\"1576766162\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XCUR\" target=\"_blank\">XCUR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527433-exicure-prices-equity-offering-shares-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exicure prices equity offering, shares down 7%</a></h4><ul><li>Exicure (<a href='https://seekingalpha.com/symbol/XCUR' title='Exicure, Inc.'>XCUR</a> <font color=\"red\">-6.8%</font>) is down out of the gate after <a href=\"https://seekingalpha.com/pr/17733256-exicure-announces-pricing-of-27_5-million-public-offering-of-common-stock\" target=\"_blank\">pricing</a> its public offering of 10M common shares at $2.75. Underwriters' over-allotment is an additional 1.5M shares. Closing date is December 23.</li><li>Yesterday's close was $2.96.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527433\" data-linked=\"Exicure prices equity offering, shares down 7%\" data-tweet=\"$XCUR - Exicure prices equity offering, shares down 7% https://seekingalpha.com/news/3527433-exicure-prices-equity-offering-shares-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3527433-exicure-prices-equity-offering-shares-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527427\" data-ts=\"1576765592\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SELB\" target=\"_blank\">SELB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527427-selecta-biosciences-out-licenses-immtor-to-asklepios-biopharmaceutical\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Selecta Biosciences out-licenses ImmTOR to Asklepios BioPharmaceutical</a></h4><ul><li>Selecta Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SELB' title='Selecta Biosciences, Inc.'>SELB</a>) is up <font color=\"green\">5%</font> premarket on robust volume in reaction to its out-licensing <a href=\"https://seekingalpha.com/pr/17733001-askbio-licenses-rights-to-selecta-biosciences-immtor-immune-tolerance-platform-for-treatment\" target=\"_blank\">agreement </a>with Asklepios BioPharmaceuticals for exclusive rights to its immune tolerance platform, ImmTOR, for use in the latter's AAV gene therapy for Pompe disease.</li><li>Under the terms of the deal, SELB is eligible to receive upfront and milestone payments up to $240M plus royalties on net sales.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527427\" data-linked=\"Selecta Biosciences out-licenses ImmTOR to Asklepios BioPharmaceutical\" data-tweet=\"$SELB - Selecta Biosciences out-licenses ImmTOR to Asklepios BioPharmaceutical https://seekingalpha.com/news/3527427-selecta-biosciences-out-licenses-immtor-to-asklepios-biopharmaceutical?source=tweet\" data-url=\"https://seekingalpha.com/news/3527427-selecta-biosciences-out-licenses-immtor-to-asklepios-biopharmaceutical\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527425\" data-ts=\"1576765359\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOPS\" target=\"_blank\">TOPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527425-tops-shipsplus-6_9-after-acquisition-of-two-tanker-newbuildings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TOPS Ships +6.9% after acquisition of two tanker newbuildings</a></h4><ul><li>TOP Ships (NASDAQ:<a href='https://seekingalpha.com/symbol/TOPS' title='Top Ships Inc.'>TOPS</a>)<font color=\"green\"> jumps 6.9%</font> in premarket trading after <a href=\"https://seekingalpha.com/pr/17733047-top-ships-inc-announces-acquisition-of-two-scrubber-fitted-eco-mr-tanker-newbuildings-time\" target=\"_blank\">acquiring</a> two companies that have new building contracts for two ultra-high specification scrubber-fitted 50,000 dwt medium-range product/chemical tankers under construction.</li><li>The company acquired 100% of the issued and outstanding shares of Santa Catalina Inc. and Santa Monica Inc. from an entity affiliated with TOPS' CEO for an aggregate purchase price of $14.35M.</li><li>Following their delivery, the vessels will enter into time charters with Trafigura Maritime Logistics Pte Ltd for a firm duration of three years, with charterer\u2019s option to extend for two additional years. TOPS is in the process of concluding financing agreements for both vessels.</li><li>\u201cThe new additions to our fleet are in line with our strategy of always operating latest technology ships and increase our gross revenue backlog for the fixed charter period of our vessels by $38.3M, which as of June 30, 2019 stood at $165.3M,\" said President and CEO Evangelos Pistiolis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527425\" data-linked=\"TOPS Ships +6.9% after acquisition of two tanker newbuildings\" data-tweet=\"$TOPS - TOPS Ships +6.9% after acquisition of two tanker newbuildings https://seekingalpha.com/news/3527425-tops-shipsplus-6_9-after-acquisition-of-two-tanker-newbuildings?source=tweet\" data-url=\"https://seekingalpha.com/news/3527425-tops-shipsplus-6_9-after-acquisition-of-two-tanker-newbuildings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527424\" data-ts=\"1576765242\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527424-cag-rad-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CAG, RAD among premarket gainers</a></h4><ul><li>Paratek Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a>) <font color=\"green\">+45%</font> on <a href=\"https://seekingalpha.com/news/3527338-paratek-nabs-barda-contract-for-nuzyra-shares-up-53-premarket\" target=\"_blank\">BARDA contract</a> for Nuzyra.</li><li>Rite Aid (NYSE:<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>) <font color=\"green\">+31%</font> on <a href=\"https://seekingalpha.com/news/3527351-rite-aid-eps-beats-0_39-beats-on-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>Catalyst Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a>) <font color=\"green\">+30%</font> on <a href=\"https://seekingalpha.com/news/3527394-catalyst-bio-up-37-premarket-on-biogen-deal-in-dry-amd\" target=\"_blank\">Biogen deal</a> in dry AMD.</li><li>Bionano Genomics (NASDAQ:<a href='https://seekingalpha.com/symbol/BNGO' title='Bionano Genomics, Inc.'>BNGO</a>) <font color=\"green\">+15%</font> after Mayo Clinic <a href=\"https://seekingalpha.com/pr/17732858-mayo-clinic-adopts-bionano-saphyr-for-applications-in-neurodegenerative-diseases\" target=\"_blank\">adopts Saphyr</a> for applications in neurodegenerative diseases.</li><li>Seadrill (NYSE:<a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited'>SDRL</a>) <font color=\"green\">+9%</font>.</li><li>Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) <font color=\"green\">+9%</font> on <a href=\"https://seekingalpha.com/news/3527356-axsome-therapeutics-up-4-premarket-after-pricing-equity-offering\" target=\"_blank\">pricing</a> equity offering.</li><li>Inovio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a>) <font color=\"green\">+8%</font>.</li><li>TiVo (NASDAQ:<a href='https://seekingalpha.com/symbol/TIVO' title='TiVo Corporation'>TIVO</a>) <font color=\"green\">+8%</font> on <a href=\"https://seekingalpha.com/news/3527354-xperi-and-tivo-to-merge\" target=\"_blank\">merger</a> with Xperi.</li><li>Conagra Brands (NYSE:<a href='https://seekingalpha.com/symbol/CAG' title='Conagra Brands, Inc.'>CAG</a>) <font color=\"green\">+7%</font> on <a href=\"https://seekingalpha.com/news/3527369-conagra-brands-eps-beats-0_06-beats-on-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li>GreenSky (NASDAQ:<a href='https://seekingalpha.com/symbol/GSKY' title='GreenSky, Inc.'>GSKY</a>) <font color=\"green\">+7%</font> after $6B <a href=\"https://seekingalpha.com/news/3527393-greenskyplus-7_4-after-6b-flow-arrangement-pact\" target=\"_blank\">flow arrangement pact</a>.</li><li>New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) <font color=\"green\">+6%</font>.</li><li>ObsEva SA (NASDAQ:<a href='https://seekingalpha.com/symbol/OBSV' title='ObsEva SA'>OBSV</a>) <font color=\"green\">+6%</font>.</li><li>The Rubicon Project (NYSE:<a href='https://seekingalpha.com/symbol/RUBI' title='the Rubicon Project, Inc.'>RUBI</a>) <font color=\"green\">+6%</font> on entering into <a href=\"https://seekingalpha.com/pr/17732675-rubicon-project-and-telaria-agree-to-combine-to-form-largest-independent-sell-side\" target=\"_blank\">stock-for-stock merger agreement</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527424\" data-linked=\"CAG, RAD among premarket gainers\" data-tweet=\"$PRTK $RAD $CBIO - CAG, RAD among premarket gainers https://seekingalpha.com/news/3527424-cag-rad-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527424-cag-rad-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527423\" data-ts=\"1576765196\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EKSO\" target=\"_blank\">EKSO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527423-ekso-down-26-premarket-on-discounted-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ekso down 26% premarket on discounted equity offering</a></h4><ul><li>Thinly traded nano cap Ekso Bionics (NASDAQ:<a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a>) slumps <font color=\"red\">26% </font>premarket on increased volume in reaction to its <a href=\"https://seekingalpha.com/pr/17732890-ekso-bionics-announces-5_0-million-registered-direct-offering\" target=\"_blank\">direct offering</a> of ~11.1M common shares and accompanying five-year warrants to purchase up to ~8.3M shares at a combined price of $0.45 to certain institutional investors. The exercise price of the warrants is $0.5402.</li><li>Yesterday's close was $0.5401.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527423\" data-linked=\"Ekso down 26% premarket on discounted equity offering\" data-tweet=\"$EKSO - Ekso down 26% premarket on discounted equity offering https://seekingalpha.com/news/3527423-ekso-down-26-premarket-on-discounted-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3527423-ekso-down-26-premarket-on-discounted-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527420\" data-ts=\"1576764794\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYNA\" target=\"_blank\">SYNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527420-synaptics-to-sell-mobile-lcd-tddi-business-shares-up-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synaptics to sell mobile LCD TDDI business; shares up 3% premarket</a></h4><ul><li>Synaptics (NASDAQ:<a href='https://seekingalpha.com/symbol/SYNA' title='Synaptics Incorporated'>SYNA</a>) has <a href=\"https://seekingalpha.com/pr/17732854-synaptics-announces-divestiture-of-mobile-lcd-tddi-business-to-hua-capital\" target=\"_blank\">agreed to sell</a> its mobile LCD TDDI unit to Hua Capital for $120M in cash. The transaction should close in Q2 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527420\" data-linked=\"Synaptics to sell mobile LCD TDDI business; shares up 3% premarket\" data-tweet=\"$SYNA - Synaptics to sell mobile LCD TDDI business; shares up 3% premarket https://seekingalpha.com/news/3527420-synaptics-to-sell-mobile-lcd-tddi-business-shares-up-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3527420-synaptics-to-sell-mobile-lcd-tddi-business-shares-up-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527418\" data-ts=\"1576764591\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527418-mlhr-apog-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MLHR, APOG among premarket losers</a></h4><ul><li>Minerva Neurosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NERV' title='Minerva Neurosciences, Inc.'>NERV</a>) <font color=\"red\">-24%</font> after MIN-117 <a href=\"https://seekingalpha.com/news/3527259-minervas-minminus-117-flunks-mid-stage-depression-study-shares-down-27-ah\" target=\"_blank\">flunks</a> mid-stage depression study.</li><li>Apogee Enterprises (NASDAQ:<a href='https://seekingalpha.com/symbol/APOG' title='Apogee Enterprises, Inc.'>APOG</a>) <font color=\"red\">-17%</font> on <a href=\"https://seekingalpha.com/news/3527330-apogee-eps-misses-0_19-misses-on-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>Xperi (NASDAQ:<a href='https://seekingalpha.com/symbol/XPER' title='Xperi Corporation'>XPER</a>) <font color=\"red\">-12%</font> on <a href=\"https://seekingalpha.com/news/3527354-xperi-and-tivo-to-merge\" target=\"_blank\">merger</a> with Tivo.</li><li>Herman Miller (NASDAQ:<a href='https://seekingalpha.com/symbol/MLHR' title='Herman Miller, Inc.'>MLHR</a>) <font color=\"red\">-10%</font> on <a href=\"https://seekingalpha.com/news/3527235-herman-miller-eps-beats-0_01-misses-on-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li>Green Dot (NYSE:<a href='https://seekingalpha.com/symbol/GDOT' title='Green Dot Corporation'>GDOT</a>) <font color=\"red\">-10%</font> on disappointing <a href=\"https://seekingalpha.com/news/3527261-green-dotminus-1_4-revenue-outlook-disappoints-ceo-and-cfo-to-exit\" target=\"_blank\">outlook</a>.</li><li>Akorn (NASDAQ:<a href='https://seekingalpha.com/symbol/AKRX' title='Akorn, Inc.'>AKRX</a>) <font color=\"red\">-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527418\" data-linked=\"MLHR, APOG among premarket losers\" data-tweet=\"$NERV $APOG $XPER - MLHR, APOG among premarket losers https://seekingalpha.com/news/3527418-mlhr-apog-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3527418-mlhr-apog-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527414\" data-ts=\"1576764271\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VTGN\" target=\"_blank\">VTGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527414-vistagenplus-19-premarket-on-positive-avminus-101-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VistaGen +19% premarket on positive AV-101 results</a></h4><ul><li>VistaGen Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a>) is up <font color=\"green\">19%</font> premarket on announcing <a href=\"https://seekingalpha.com/pr/17733040-vistagen-and-baylor-college-of-medicine-announce-successful-results-of-first-step-target\" target=\"_blank\">successful results</a> from a first-step, Phase 1b clinical study with healthy U.S. military Veterans, which measured NMDAR (N-methyl-D-aspartate receptor) target engagement of VistaGen's AV-101, for potential treatment of suicidal ideation in Veterans.</li><li>In the Phase 1b target engagement study, 10 healthy volunteer Veterans from Operation Enduring Freedom, Operation Iraqi Freedom or Operation New Dawn received single doses of AV-101 (720 mg and 1440 mg) and placebo.</li><li>The primary goal was to identify and define a dose-response relationship between AV-101 and multiple electrophysiological &#40;EEG&#41; biomarkers, as well as blood biomarkers associated with suicidality.</li><li>The findings suggest that, the higher dose of AV-101 (1440 mg) was associated with dose-related increase in the 40 Hz Auditory Steady State Response, a robust measure of the integrity of inhibitory interneuron synchronization.</li><li>Both doses of AV-101 were well-tolerated, and there were no dissociative adverse events or serious adverse events.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527414\" data-linked=\"VistaGen +19% premarket on positive AV-101 results\" data-tweet=\"$VTGN - VistaGen +19% premarket on positive AV-101 results https://seekingalpha.com/news/3527414-vistagenplus-19-premarket-on-positive-avminus-101-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3527414-vistagenplus-19-premarket-on-positive-avminus-101-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527405\" data-ts=\"1576763393\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SELB\" target=\"_blank\">SELB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527405-selecta-bio-completes-enrollment-in-selminus-212-study-shares-up-23-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Selecta Bio completes enrollment in SEL-212 study; shares up 23% premarket</a></h4><ul><li>Thinly traded nano cap Selecta Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/SELB' title='Selecta Biosciences, Inc.'>SELB</a>) is up <font color=\"green\">23% </font>premarket on increased volume in response to the <a href=\"https://seekingalpha.com/pr/17732987-selecta-biosciences-announces-completion-of-enrollment-in-head-to-head-compare-trial-of\" target=\"_blank\">completion of enrollment</a> in a 150-subject Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03905512?cond=gout&amp;lead=selecta+biosciences&amp;phase=1&amp;draw=2&amp;rank=1\" target=\"_blank\">COMPARE</a>, evaluating lead candidate SEL-212 (ImmTOR + pegadricase) versus a bi-weekly dose of pegloticase [Horizon Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/HZNP' title='Horizon Therapeutics Public Limited Company'>HZNP</a>) Krystexxa] in patients with chronic treatment-resistant gout.</li><li>The primary endpoint is the maintenance of serum uric acid levels below 6 mg/dL (normal ranges for women and men: 2.4-6.0 mg/dL and 3.4-7.0 mg/dL, respectively) at months 3 &amp; 6. Topline data should be available by mid-2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527405\" data-linked=\"Selecta Bio completes enrollment in SEL-212 study; shares up 23% premarket\" data-tweet=\"$SELB $HZNP - Selecta Bio completes enrollment in SEL-212 study; shares up 23% premarket https://seekingalpha.com/news/3527405-selecta-bio-completes-enrollment-in-selminus-212-study-shares-up-23-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3527405-selecta-bio-completes-enrollment-in-selminus-212-study-shares-up-23-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527394\" data-ts=\"1576762180\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBIO\" target=\"_blank\">CBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527394-catalyst-bio-up-37-premarket-on-biogen-deal-in-dry-amd\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catalyst Bio up 37% premarket on Biogen deal in dry AMD</a></h4><ul><li>Thinly traded nano cap Catalyst Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a>) is up <font color=\"green\">37%</font> premarket on increased volume in reaction to its global license and collaboration <a href=\"https://seekingalpha.com/pr/17732885-catalyst-biosciences-announces-global-license-and-collaboration-agreement-to-develop\" target=\"_blank\">agreement </a>with Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) to develop and commercialize C3 protease inhibitor CB 2782 (CB 2782-PEG) for the potential treatment of patients with geographic atrophy associated with dry age-related macular degeneration (dry AMD).</li><li>Catalyst will be responsible for preclinical studies and manufacturing. Biogen will fund both and will be responsible for IND-enabling activities, worldwide clinical development and commercialization.</li><li>Under the terms of the agreement, Catalyst will receive $15M upfront, up to $340M in milestones and tiered royalties on net sales.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527394\" data-linked=\"Catalyst Bio up 37% premarket on Biogen deal in dry AMD\" data-tweet=\"$CBIO $BIIB - Catalyst Bio up 37% premarket on Biogen deal in dry AMD https://seekingalpha.com/news/3527394-catalyst-bio-up-37-premarket-on-biogen-deal-in-dry-amd?source=tweet\" data-url=\"https://seekingalpha.com/news/3527394-catalyst-bio-up-37-premarket-on-biogen-deal-in-dry-amd\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527393\" data-ts=\"1576761940\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSKY\" target=\"_blank\">GSKY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527393-greenskyplus-7_4-after-6b-flow-arrangement-pact\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GreenSky +7.4% after $6B flow arrangement pact</a></h4><ul><li>GreenSky (NASDAQ:<a href='https://seekingalpha.com/symbol/GSKY' title='GreenSky, Inc.'>GSKY</a>) <font color=\"green\">jumps 7.4%</font> in premarket trading after it<a href=\"https://seekingalpha.com/pr/17732863-greensky-strengthens-extends-and-diversifies-funding-commitments\" target=\"_blank\"> reaches an agreement</a> in principle for a three-year, $6B forward flow arrangement with a leading institutional asset manager.</li><li>Also, the company renews its agreement with its largest bank partner for an additional year, extended a second bank partner agreement for an additional three years, and reached an agreement to increase a third bank partner commitment by $100M.</li><li>The $6B forward flow full risk transfer funding commitment has pricing that \"closely approximates our current bank partner economics,\" said Chairman and CEO David Zalik.</li><li>These funding relationships \"yield both flexibility and significant liquidity to fuel future growth,\" he said.</li><li>Additionally, GreenSky said its strategic alternatives review, which it announced in August, in ongoing. It doesn't intend to make further public comment unless and until the board approves a specific transaction or alternative or otherwise concludes the review.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527393\" data-linked=\"GreenSky +7.4% after $6B flow arrangement pact\" data-tweet=\"$GSKY - GreenSky +7.4% after $6B flow arrangement pact https://seekingalpha.com/news/3527393-greenskyplus-7_4-after-6b-flow-arrangement-pact?source=tweet\" data-url=\"https://seekingalpha.com/news/3527393-greenskyplus-7_4-after-6b-flow-arrangement-pact\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527392\" data-ts=\"1576761878\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSCO\" target=\"_blank\">CSCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527392-cisco-edges-higher-after-barclays-boost\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cisco edges higher after Barclays boost</a></h4><ul> <li>Barclays upgrades Cisco (NASDAQ:<a href='https://seekingalpha.com/symbol/CSCO' title='Cisco Systems, Inc.'>CSCO</a>) to an Overweight rating after having the IT/networking company slotted at Equal-weight.</li> <li>The firm assigns a price target of $53 to Cisco to rep 14% upside potential.</li> <li>Shares of Cisco are <font color=\"green\">up 1.16%</font> premarket to $47.18 vs. the 52-week trading range of $40.25 to $58.26.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527392\" data-linked=\"Cisco edges higher after Barclays boost\" data-tweet=\"$CSCO - Cisco edges higher after Barclays boost https://seekingalpha.com/news/3527392-cisco-edges-higher-after-barclays-boost?source=tweet\" data-url=\"https://seekingalpha.com/news/3527392-cisco-edges-higher-after-barclays-boost\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527387\" data-ts=\"1576761130\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAG\" target=\"_blank\">CAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527387-conagra-brandsplus-7-after-earnings-topper\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ConAgra Brands +7% after earnings topper</a></h4><ul> <li>ConAgra Brands (NYSE:<a href='https://seekingalpha.com/symbol/CAG' title='Conagra Brands, Inc.'>CAG</a>) jumps in early trading after sailing past <a href=\"https://seekingalpha.com/pr/17732781-conagra-brands-reports-solid-second-quarter-results\" target=\"_blank\">FQ2</a> estimates and posting solid guidance.</li> <li>\"Our expectation for fiscal 2020 remains that first-half investments will result in strong second-half performance. The second-half is when we expect to see the greatest impact from new frozen and snacks innovation, continued smart promotional support in key grocery brands, the ongoing implementation of our Pinnacle action plan, and synergy capture,\" say ConAgra CEO Sean Connolly.</li> <li>The company expects FY20 revenue growth of +12.4% to +12.9% vs. +13.5% to +14.0% prior view and +12.3% consensus. EPS $2.07 to $2.17 is anticipated vs. a prior view for $2.08 to $2.18 and $2.09 consensus. ConAgra also sees adjusted operating margin falling in a range of 16.2% to 16.8% for the year.</li> <li>Shares of ConAgra are <font color=\"green\">up 7.06%</font> premarket to $31.10.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3527369-conagra-brands-eps-beats-0_06-beats-on-revenue\" target=\"_blank\">ConAgra Brands EPS beats by $0.06, beats on revenue</a> (Dec. 19)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527387\" data-linked=\"ConAgra Brands +7% after earnings topper\" data-tweet=\"$CAG - ConAgra Brands +7% after earnings topper https://seekingalpha.com/news/3527387-conagra-brandsplus-7-after-earnings-topper?source=tweet\" data-url=\"https://seekingalpha.com/news/3527387-conagra-brandsplus-7-after-earnings-topper\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527384\" data-ts=\"1576760659\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAFM\" target=\"_blank\">SAFM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527384-sanderson-farmsplus-3-on-improved-pricing-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanderson Farms +3% on improved pricing outlook</a></h4><ul> <li>Sanderson Farms (NASDAQ:<a href='https://seekingalpha.com/symbol/SAFM' title='Sanderson Farms, Inc.'>SAFM</a>) trades higher after reporting revenue growth of 13.6% in <a href=\"https://seekingalpha.com/pr/17732783-sanderson-farms-inc-reports-results-for-fourth-quarter-and-fiscal-2019\" target=\"_blank\">FQ4</a> and seeing a shift in the poultry product story.</li> <li>\"Despite weakness during our fourth fiscal quarter, overall market prices for poultry moved counter-cyclically higher during November and December, and several factors are expected to support higher market prices for poultry meat as we move into the new calendar year. The protein deficit caused by African swine fever in China and other countries, recently well-publicized chicken sandwich features at quick serve restaurants, and expected higher retail pork and beef prices should all support stronger poultry markets as we move into 2020,\" notes Sanderson Farms CEO Joel Sanderson.</li> <li>Increased promotional activity for chicken sandwiches at quick-serve restaurants and higher expected prices for beef and pork are also seen supporting a stronger poultry market in 2020.</li> <li>Shares of Sanderson Farms are <font color=\"green\">up 3.22%</font> premarket to $172.50.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3527370-sanderson-farms-eps-beats-0_22-beats-on-revenue\" target=\"_blank\">Sanderson Farms EPS beats by $0.22, beats on revenue</a> (Dec. 19)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527384\" data-linked=\"Sanderson Farms +3% on improved pricing outlook\" data-tweet=\"$SAFM - Sanderson Farms +3% on improved pricing outlook https://seekingalpha.com/news/3527384-sanderson-farmsplus-3-on-improved-pricing-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3527384-sanderson-farmsplus-3-on-improved-pricing-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527381\" data-ts=\"1576760398\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAD\" target=\"_blank\">RAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527381-rite-aid-up-22-premarket-on-q3-beat-non-gaap-eps-guidance-raised\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rite Aid up 22% premarket on Q3 beat; non-GAAP EPS guidance raised</a></h4><ul><li>Rite Aid (<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>) <a href=\"https://seekingalpha.com/pr/17732717-rite-aid-corporation-reports-fiscal-2020-third-quarter-results\" target=\"_blank\">Q3 results</a>: Revenues: $5,462.3M (+0.2%); Retail Pharmacy Segment: $3,909.9M (-1.7%); Pharmacy Services Segment: $1,613.1M (+5.7%).</li><li>Net Income: $52.3M; EPS: $0.98; non-GAAP Net Income: $29.1M (+98.0%); non-GAAP EPS: $0.54 (+92.9%); CF Ops: $423.7M (+20.7%).</li><li><strong>FY 2020 guidance</strong>: Revenues: $21.5B-$21.9B (unch); net loss: ($174M)-(204M) from ($235M)-(275M); non-GAAP EPS: $0.13-$0.55 from $0.00-$0.56; non-GAAP EBITDA: $515M-$545M from $510M-$550M; Capex: ~$230M from ~$250M.</li><li>Shares are up <font color=\"green\">22%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527381\" data-linked=\"Rite Aid up 22% premarket on Q3 beat; non-GAAP EPS guidance raised\" data-tweet=\"$RAD - Rite Aid up 22% premarket on Q3 beat; non-GAAP EPS guidance raised https://seekingalpha.com/news/3527381-rite-aid-up-22-premarket-on-q3-beat-non-gaap-eps-guidance-raised?source=tweet\" data-url=\"https://seekingalpha.com/news/3527381-rite-aid-up-22-premarket-on-q3-beat-non-gaap-eps-guidance-raised\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527379\" data-ts=\"1576760171\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527379-amarin-down-2-premarket-on-bearish-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amarin down 2% premarket on bearish report</a></h4><ul><li>Amarin (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation plc'>AMRN</a>) slips <font color=\"red\">2%</font> premarket on light volume on the heels of a <a href=\"https://medicalresearchcollaborative.com/reports?product_id=51\" target=\"_blank\">cautious report</a> from Medical Research Collaborative who questions the robustness of Vascepa's intellectual property.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527379\" data-linked=\"Amarin down 2% premarket on bearish report\" data-tweet=\"$AMRN - Amarin down 2% premarket on bearish report https://seekingalpha.com/news/3527379-amarin-down-2-premarket-on-bearish-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3527379-amarin-down-2-premarket-on-bearish-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>134&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527376\" data-ts=\"1576759798\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIMT\" target=\"_blank\">AIMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527376-barclays-sees-21-upside-in-j-and-j-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays sees 21% upside in J&amp;J in premarket analyst action</a></h4><ul><li>Aimmune Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AIMT' title='Aimmune Therapeutics, Inc.'>AIMT</a>) initiated with Neutral rating and $33 (4% upside) price target at H.C. Wainwright.</li><li>Ampio Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/AMPE' title='Ampio Pharmaceuticals, Inc.'>AMPE</a>) initiated with Buy rating and $4 (888% upside) price target at Roth Capital. Shares up <font color=\"green\">11% </font>premarket.</li><li>Apellis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/APLS' title='Apellis Pharmaceuticals, Inc.'>APLS</a>) initiated with Buy rating and $36 (29% upside) price target at BofA.</li><li>Arvinas (NASDAQ:<a href='https://seekingalpha.com/symbol/ARVN' title='Arvinas, Inc.'>ARVN</a>) initiated with Buy rating and $50 (22% upside) price target at H.C. Wainwright. Shares down <font color=\"red\">1% </font>premarket.</li><li>Global Blood Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics, Inc.'>GBT</a>) resumed with Overweight rating and $90 (19% upside) price target at JPMorgan.</li><li>INmune Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/INMB' title='INmune Bio Inc.'>INMB</a>) initiated with Buy rating and $13 (128% upside) price target at Roth.</li><li>Inovio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/INO' title='Inovio Pharmaceuticals, Inc.'>INO</a>) initiated with Buy rating and $13 (394% upside) price target at Roth. Shares up <font color=\"green\">12% </font>premarket.</li><li>Karuna Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KRTX' title='Karuna Therapeutics, Inc.'>KRTX</a>) initiated with Buy rating and $126 (91% upside) price target at Stifel.</li><li>MacroGenics (NASDAQ:<a href='https://seekingalpha.com/symbol/MGNX' title='MacroGenics, Inc.'>MGNX</a>) initiated with Overweight rating and $17 (61% upside) price target at Cantor Fitzgerald.</li><li>Mesoblast (NASDAQ:<a href='https://seekingalpha.com/symbol/MESO' title='Mesoblast Limited'>MESO</a>) initiated with Buy rating and $14 (107% upside) price target at Dawson James Securities.</li><li>Elanco Animal Health (NYSE:<a href='https://seekingalpha.com/symbol/ELAN' title='Elanco Animal Health Incorporated'>ELAN</a>) upgraded to Buy with a $34 (21% upside) price target at BofA.</li><li>Johnson &amp; Johnson (NYSE:<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>) upgraded to Overweight with a $173 (21% upside) price target at Barclays. Shares up <font color=\"green\">1% </font>premarket.</li><li>Quest Diagnostics (NYSE:<a href='https://seekingalpha.com/symbol/DGX' title='Quest Diagnostics Incorporated'>DGX</a>) upgraded to Neutral with a $110 (3% upside) price target at BofA. Shares up <font color=\"green\">1% </font>premarket.</li><li>Boston Scientific (NYSE:<a href='https://seekingalpha.com/symbol/BSX' title='Boston Scientific Corporation'>BSX</a>) downgraded to Buy with a $53 (18% upside) price target at Needham.</li><li>Synthorx (NASDAQ:<a href='https://seekingalpha.com/symbol/THOR' title='Synthorx, Inc.'>THOR</a>) downgraded to Hold with a $68 (flat) price target at Jefferies.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527376\" data-linked=\"Barclays sees 21% upside in J&amp;J in premarket analyst action\" data-tweet=\"$AIMT $AMPE $APLS - Barclays sees 21% upside in J&amp;J in premarket analyst action https://seekingalpha.com/news/3527376-barclays-sees-21-upside-in-j-and-j-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3527376-barclays-sees-21-upside-in-j-and-j-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527375\" data-ts=\"1576759336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527375-micron-calls-bottom-wsjs-heard\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron calls the bottom - WSJ&#39;s &#39;Heard&#39;</a></h4><ul><li>The current quarter is \"the cyclical bottom for our financial performance,\" said the company last night, <a href=\"https://www.wsj.com/articles/micron-calls-the-bottom-11576712235\" target=\"_blank\">as noted by the WSJ's Dan Gallagher</a>.</li><li><a href=\"https://seekingalpha.com/article/4313261-micron-technology-inc-mu-ceo-sanjay-mehrotra-on-q1-2020-results-earnings-call-transcript\" target=\"_blank\">Last night's conference call transcript</a></li><li>To review, Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a>) in its FQ1 posted its fifth-straight quarter of double-digit revenue declines, and the outlook for the February Q is for six straight.</li><li>Markets do anticipate though, and they've clearly been pricing in a rebound in the company's results for some time - shares are <font color=\"green\">up about 75%</font> this year. With the stock changing hands at about 19x forward earnings - or double the average valuation over the last three years - the turnaround needs to come soon, says Gallagher.</li><li>Checking the Sell-Side, RBC lifts its price target to $65 from $55, and Rosenblatt to $100 from $80.</li><li>Shares are <font color=\"green\">up 3.65%</font> premarket to $54.98.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527375\" data-linked=\"Micron calls the bottom - WSJ&#39;s &#39;Heard&#39;\" data-tweet=\"$MU - Micron calls the bottom - WSJ&#39;s &#39;Heard&#39; https://seekingalpha.com/news/3527375-micron-calls-bottom-wsjs-heard?source=tweet\" data-url=\"https://seekingalpha.com/news/3527375-micron-calls-bottom-wsjs-heard\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>96&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527369\" data-ts=\"1576758650\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAG\" target=\"_blank\">CAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527369-conagra-brands-eps-beats-0_06-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ConAgra Brands EPS beats by $0.06, beats on revenue</a></h4><ul><li>ConAgra Brands (NYSE:<a href='https://seekingalpha.com/symbol/CAG' title='Conagra Brands, Inc.'>CAG</a>): Q2 Non-GAAP EPS of $0.63 <font color=\"green\">beats by $0.06</font>; GAAP EPS of $0.53 <font color=\"red\">misses by $0.03</font>.</li><li>Revenue of $2.82B (+18.5% Y/Y) <font color=\"green\">beats by $20M</font>.</li><li>Shares <font color=\"green\">+6.71%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17732781-conagra-brands-reports-solid-second-quarter-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3527369\" data-linked=\"ConAgra Brands EPS beats by $0.06, beats on revenue\" data-tweet=\"$CAG - ConAgra Brands EPS beats by $0.06, beats on revenue https://seekingalpha.com/news/3527369-conagra-brands-eps-beats-0_06-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3527369-conagra-brands-eps-beats-0_06-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527366\" data-ts=\"1576758577\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRI\" target=\"_blank\">DRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527366-darden-restaurantsminus-4-after-olive-garden-drags\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Darden Restaurants -4% after Olive Garden drags</a></h4><ul> <li>Darden Restaurants (NYSE:<a href='https://seekingalpha.com/symbol/DRI' title='Darden Restaurants, Inc.'>DRI</a>) reports comparable sales across chains increased 2.0% in <a href=\"https://seekingalpha.com/pr/17732731-darden-restaurants-reports-fiscal-2020-second-quarter-results-declares-regular-quarterly\" target=\"_blank\">FQ2</a> vs. +2.1% consensus.</li> <li>Comparable sales were up 1.5% at the Olive Garden Chain vs. +3.1% consensus off a 1.2% drop in customer traffic and 2.0% jump in prices.</li> <li>Comparable sales rose 6.7% at the LongHorn chain vs. +2.9% consensus off a 3.2% gain in traffic and 1.9% increase in pricing.</li> <li>Darden's overall restaurant margin was 19.7% of sales vs. 19.3% consensus.</li><li>Looking ahead, Darden anticipates full-year revenue growth of +5.3% to +6.3% and EPS of $6.30 to $6.45 vs. $6.40 consensus. Total capital spending of $450M to $500M is anticipated.</li> <li>Shares of Darden Restaurants are <font color=\"red\">down 4.39%</font> premarket to $111.20.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3527352-darden-restaurants-eps-beats-0_05-revenue-in-line\" target=\"_blank\">Darden Restaurants EPS beats by $0.05,  revenue in-line</a> (Dec. 19)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527366\" data-linked=\"Darden Restaurants -4% after Olive Garden drags\" data-tweet=\"$DRI - Darden Restaurants -4% after Olive Garden drags https://seekingalpha.com/news/3527366-darden-restaurantsminus-4-after-olive-garden-drags?source=tweet\" data-url=\"https://seekingalpha.com/news/3527366-darden-restaurantsminus-4-after-olive-garden-drags\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527362\" data-ts=\"1576758445\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXEL\" target=\"_blank\">EXEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527362-exelixis-teams-up-roche-in-cancer-shares-up-3-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exelixis teams up with Roche in cancer; shares up 3% premarket</a></h4><ul><li>Exelixis (NASDAQ:<a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a>) inks an <a href=\"https://seekingalpha.com/pr/17732710-exelixis-enters-clinical-collaboration-for-three-phase-3-combination-trials-for-patients\" target=\"_blank\">agreement</a> with Roche (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding AG'>OTCQX:RHHBY</a>) aimed at evaluating the combination of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) for the treatment of patients with locally advanced or metastatic solid tumors.</li><li>The companies will co-fund three late-stage studies in advanced non-small cell lung cancer, castration-resistant prostate cancer and renal cell carcinoma.</li><li>EXEL is up <font color=\"green\">3%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527362\" data-linked=\"Exelixis teams up with Roche in cancer; shares up 3% premarket\" data-tweet=\"$EXEL $RHHBY - Exelixis teams up with Roche in cancer; shares up 3% premarket https://seekingalpha.com/news/3527362-exelixis-teams-up-roche-in-cancer-shares-up-3-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3527362-exelixis-teams-up-roche-in-cancer-shares-up-3-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527359\" data-ts=\"1576758218\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLT\" target=\"_blank\">TLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527359-this-just-in-10-year-yield-nears-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">This just in: 10-year yield nears 2%</a></h4><ul><li>There's been loads of whipsaw action in the bond market of late, so it's hard to make too much of the move. But for now - with a number of geopolitical risks having passed, and with the U.S. economy continuing to move forward - yields have resolved to the upside.</li><li>Just in the past week, the China trade war has cooled, the U.K. elections have apparently resolved Brexit, and the Fed officially went into a long pause mode.</li><li>The 10-year Treasury yield is up another 2.3 basis points this morning to 1.94% - that's the highest level since August. <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a> <font color=\"red\">-0.25%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a> <font color=\"green\">+0.5%</font>, <a href='https://seekingalpha.com/symbol/AGG' title='iShares Core U.S. Aggregate Bond ETF'>AGG</a> <font color=\"red\">-0.1%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3527359\" data-linked=\"This just in: 10-year yield nears 2%\" data-tweet=\"$TLT $TBT $AGG - This just in: 10-year yield nears 2% https://seekingalpha.com/news/3527359-this-just-in-10-year-yield-nears-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3527359-this-just-in-10-year-yield-nears-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527356\" data-ts=\"1576757584\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXSM\" target=\"_blank\">AXSM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527356-axsome-therapeutics-up-4-premarket-after-pricing-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Axsome Therapeutics up 4% premarket after pricing equity offering</a></h4><ul><li>Axsome Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AXSM' title='Axsome Therapeutics, Inc.'>AXSM</a>) <a href=\"https://seekingalpha.com/pr/17732767-axsome-therapeutics-announces-pricing-of-public-offering-of-174-million-of-shares-of-common\" target=\"_blank\">prices</a> its public offering of 2M common shares at $87 per share. Underwriters' overallotment is an additional 300K shares. Closing date is December 23.</li><li>Yesterday's close was $89.57.</li><li>Shares up <font color=\"green\">4%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527356\" data-linked=\"Axsome Therapeutics up 4% premarket after pricing equity offering\" data-tweet=\"$AXSM - Axsome Therapeutics up 4% premarket after pricing equity offering https://seekingalpha.com/news/3527356-axsome-therapeutics-up-4-premarket-after-pricing-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3527356-axsome-therapeutics-up-4-premarket-after-pricing-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527354\" data-ts=\"1576757265\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TIVO\" target=\"_blank\">TIVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527354-xperi-and-tivo-to-merge\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xperi and Tivo to merge</a></h4><ul> <li>Xperi Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/XPER' title='Xperi Corporation'>XPER</a>) and TiVo (NASDAQ:<a href='https://seekingalpha.com/symbol/TIVO' title='TiVo Corporation'>TIVO</a>) plan to merge in a $3B all-stock transaction.</li><li>The companies say the transaction creates a leading consumer and entertainment technology business and one of the industry\u2019s largest intellectual property licensing platforms with a diverse portfolio of entertainment and semiconductor intellectual property.</li> <li>The merger pact calls for a 0.455 fixed exchange ratio, meaning Xperi shareholders will own approximately 46.5% of the combined business and TiVo shareholders will own approximately 53.5%.</li><li>The deal is expected to close in Q2 of 2020.</li><li>TIVO  <font color=\"green\">+8.23%</font> premarket to  $8.54.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17732721-xperi-and-tivo-to-combine-creating-leader-in-consumer-entertainment-technology-and-ip\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3527354\" data-linked=\"Xperi and Tivo to merge\" data-tweet=\"$TIVO $XPER $XPER - Xperi and Tivo to merge https://seekingalpha.com/news/3527354-xperi-and-tivo-to-merge?source=tweet\" data-url=\"https://seekingalpha.com/news/3527354-xperi-and-tivo-to-merge\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527351\" data-ts=\"1576756977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAD\" target=\"_blank\">RAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527351-rite-aid-eps-beats-0_39-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rite Aid EPS beats by $0.39, beats on revenue</a></h4><ul><li>Rite Aid (NYSE:<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>): Q3 Non-GAAP EPS of $0.54 <font color=\"green\">beats by $0.39</font>; GAAP EPS of $0.98.</li><li>Revenue of $5.46B (+0.2% Y/Y) <font color=\"green\">beats by $40M</font>.</li><li>Shares <font color=\"green\">+2%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17732717-rite-aid-corporation-reports-fiscal-2020-third-quarter-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3527351\" data-linked=\"Rite Aid EPS beats by $0.39, beats on revenue\" data-tweet=\"$RAD - Rite Aid EPS beats by $0.39, beats on revenue https://seekingalpha.com/news/3527351-rite-aid-eps-beats-0_39-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3527351-rite-aid-eps-beats-0_39-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>60&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527341\" data-ts=\"1576756746\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527341-wedbush-sees-upside-on-splunk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wedbush sees upside on Splunk</a></h4><ul> <li>Splunk (NASDAQ:<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a>) is a new addition to the Best Ideas List at Wedbush Securities.</li> <li>The firm assigns a price target of $180 to Splunk vs. the average sell-side PT of $157.61.</li> <li>Shares of Splunk are <font color=\"green\">up 0.57%</font> in premarket trading to $148.94.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3527341\" data-linked=\"Wedbush sees upside on Splunk\" data-tweet=\"$SPLK - Wedbush sees upside on Splunk https://seekingalpha.com/news/3527341-wedbush-sees-upside-on-splunk?source=tweet\" data-url=\"https://seekingalpha.com/news/3527341-wedbush-sees-upside-on-splunk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527338\" data-ts=\"1576756097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTK\" target=\"_blank\">PRTK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527338-paratek-nabs-barda-contract-for-nuzyra-shares-up-53-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Paratek nabs BARDA contract for Nuzyra; shares up 53% premarket</a></h4><ul> <li>Paratek Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTK' title='Paratek Pharmaceuticals, Inc.'>PRTK</a>) has been <a href=\"https://seekingalpha.com/pr/17732436-paratek-awarded-barda-project-bioshield-contract-for-nuzyra\" target=\"_blank\">awarded a 5-year extendable contract</a> to support the development of NUZYRA (omadacycline) for the treatment of pulmonary anthrax, FDA post-marketing requirements &#40;PMR&#41; associated with the initial NUZYRA approval, and the option to procure up to 10,000 treatment courses of NUZYRA for the Strategic National Stockpile &#40;SNS&#41; for use against potential biothreats.</li>    <li>Under the terms of the agreement, BARDA will award initial funding of ~$59M and the purchase of an initial 2,500 treatment courses to add to the current SNS.</li><li>The contract provides for additional potential time-based funding, including: ~$77M for PMR commitments and ~$20M for manufacturing-related requirements.</li><li>The remaining staged, milestone-based funding includes the potential for ~$13M and ~$115M for development of NUZYRA and three additional purchases.</li>  <li>NUZYRA is a broad spectrum, once-daily oral and intravenous modernized tetracycline to treat community-acquired pneumonia and skin infections.</li><li>Shares are up <font color=\"green\">53%</font> premarket.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3527338\" data-linked=\"Paratek nabs BARDA contract for Nuzyra; shares up 53% premarket\" data-tweet=\"$PRTK - Paratek nabs BARDA contract for Nuzyra; shares up 53% premarket https://seekingalpha.com/news/3527338-paratek-nabs-barda-contract-for-nuzyra-shares-up-53-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3527338-paratek-nabs-barda-contract-for-nuzyra-shares-up-53-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3527331\" data-ts=\"1576755302\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JNJ\" target=\"_blank\">JNJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3527331-j-and-js-spravato-okd-in-europe-for-treatment-resistant-depression\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J&amp;J&#39;s Spravato OK&#39;d in Europe for treatment-resistant depression</a></h4><ul><li>As expected, the European Commission <a href=\"https://www.afp.com/en/news/1315/spravatorv-esketamine-nasal-spray-approved-europe-adults-treatment-resistant-major-depressive-disorder-201912190052721\" target=\"_blank\">approves</a> Johnson &amp; Johnson (NYSE:<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a>) unit Janssen Pharmaceutical Companies' Spravato (esketamine) nasal spray for the treatment of adults with treatment-resistant major depressive disorder.</li><li>Two months ago, the advisory group CHMP adopted a <a href=\"https://seekingalpha.com/news/3506852-european-advisory-group-backs-j-and-j-antidepressant-spravato\" target=\"_blank\">positive opinion</a> backing approval.</li><li>Shares up <font color=\"green\">1%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3527331\" data-linked=\"J&amp;J&#39;s Spravato OK&#39;d in Europe for treatment-resistant depression\" data-tweet=\"$JNJ - J&amp;J&#39;s Spravato OK&#39;d in Europe for treatment-resistant depression https://seekingalpha.com/news/3527331-j-and-js-spravato-okd-in-europe-for-treatment-resistant-depression?source=tweet\" data-url=\"https://seekingalpha.com/news/3527331-j-and-js-spravato-okd-in-europe-for-treatment-resistant-depression\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":61,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}